| Temporary vascular occlusion with poloxamer 407. | |
| | |
MedLine Citation:
|
PMID: 15046888 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
There is a need for safe and reversible occlusions during percutaneous endovascular procedures. Poloxamer 407 is a non-ionic surfactant with rapid reversible sol-gel transition behaviour. The safety and efficacy of this polymer as a temporary embolic agent was investigated. First, dissolution time after gelation of poloxamer was determined in an in vitro model. Then, transient poloxamer occlusion of renal and pulmonary arteries of seven dogs was followed by serial angiograms. Macroscopic and pathological changes were studied 1 week later. This experiment was repeated in similar arteries in one pig, and in auricular arteries of two rabbits. Poloxamer dissolution after in vitro polymerization was completed within 1-20 h, depending on concentrations. In vivo poloxamer 22% injections led to complete occlusion, followed by full recanalization within 10-90 min without complication. The only biochemical effect of poloxamer occlusions was transient elevation of triglyceride levels. There were no pathological abnormalities at 1 week. Poloxamer 407 could be used as an embolic material for temporary occlusions. |
| | |
Authors:
|
Jean Raymond; Annick Metcalfe; Igor Salazkin; Alexander Schwarz |
Related Documents
:
|
15452078 - Hyperoxia promotes electroretinogram recovery after retinal artery occlusion in cats. 340648 - Lingualized occlusion for removable prosthodontics. 17297018 - The vascular plug: a new device for parent artery occlusion. 19118738 - Cellular and molecular mechanism regulating blood flow recovery in acute versus gradual... 16360368 - Tissue doppler velocities of the right and left ventricles and their association with c... 18398348 - Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor in... |
Publication Detail:
|
Type: Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Biomaterials Volume: 25 ISSN: 0142-9612 ISO Abbreviation: Biomaterials Publication Date: 2004 Aug |
Date Detail:
|
Created Date: 2004-03-29 Completed Date: 2004-12-08 Revised Date: 2006-11-15 |
Medline Journal Info:
|
Nlm Unique ID: 8100316 Medline TA: Biomaterials Country: England |
Other Details:
|
Languages: eng Pagination: 3983-9 Citation Subset: IM |
Affiliation:
|
Interventional Neuroradiology Laboratory, CHUM Research Center, Notre-Dame Hospital, Mailloux Pavilion M-8206, 1560 Sherbrooke East, Montreal, Que., Canada H2L 4M1. dr_jean_raymond@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Arteries / cytology*, drug effects, physiology* Dogs Embolization, Therapeutic / methods* Materials Testing Poloxamer / administration & dosage*, analysis, pharmacokinetics* Rabbits Species Specificity Swine Veins / cytology*, drug effects, physiology* |
| Chemical | |
Reg. No./Substance:
|
106392-12-5/Poloxamer |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: A preliminary study on chitosan and gelatin polyelectrolyte complex cytocompatibility by cell cycle ...
Next Document: Microcellular polyHIPE polymer supports osteoblast growth and bone formation in vitro.